Chi-Med IPO reflects ambition to go global

15 April 2019

Hutchinson China MedTech Limited has never downplayed the extent of its ambition to put Chinese drug development on the map, so clearly it has not held back with the hyperbole on announcing its upcoming global offering on the Stock Exchange of Hong Kong (SEHK).

The company, which calls itself Chi-Med, currently trades on the AIM market of the London Stock Exchange and its American Depositary Shares, each representing one-half of one Share, are listed on the Nasdaq Global Select Market.

Chi-Med is focused on discovery, development and commercialization of targeted therapies and immunotherapies for oncology and immunological diseases, and has collaborations with companies including AstraZeneca (LSE: AZN) and Eli Lilly (NYSE: LLY).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK